Literature DB >> 10645978

Detection of specific antibody isotypes and subtypes before and after treatment of American visceral leishmaniasis.

V L da Matta1, S Hoshino-Shimizu, R Dietze, C E Corbett.   

Abstract

Sera from patients with American visceral leishmaniasis (AVL) were studied before and after treatment based on their antibody isotypes and subtypes. The study was comprised of 33 Brazilian patients with well-defined diagnosis of AVL and 39 clinically healthy individuals. Antileishmanial antibody isotypes and subtypes were observed in almost all patients, except IgA that was detected in about 63% of them. The sensitivity and specificity of the immunofluorescence assay in the detection of antibody isotypes (IgG and IgM) and subtypes (IgG1, IgG2, IgG3, and IgG4) were high with no statistical difference, ranging from 0.937 to 1.000 and from 0.954 to 1.000, respectively. All IgG antibodies and its subtypes had their levels reduced after treatment. However, the IgG4 had an early decay and its conversion to negative was significantly high in children. Moreover, the profile of IgG4 before treatment corresponded to a unimodal curve that shifted to a patent bimodal curve after treatment, indicative of therapeutic success. Thus, the IgG4 shows to be a suitable immunological marker for the assessment of chemotherapy in AVL patients or communities. Our findings suggest that IgG4 correlates with IL-4 that also decreases after therapy. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10645978      PMCID: PMC6807925          DOI: 10.1002/(sici)1098-2825(2000)14:1<5::aid-jcla2>3.0.co;2-f

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  46 in total

1.  Visceral leishmaniasis in AIDS patient.

Authors:  E L Nicodemo; M I Duarte; C E Corbett; A C Nicodemo; V L Matta; R Chebabo; V Amato Neto
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1990 Jul-Aug       Impact factor: 1.846

2.  Immunoglobulin G subclass-specific antileishmanial antibody responses in Indian kala-azar and post-kala-azar dermal leishmaniasis.

Authors:  A K Ghosh; S Dasgupta; A C Ghose
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

3.  Pre- and post-treatment antibody levels in visceral leishmaniasis.

Authors:  A Hailu
Journal:  Trans R Soc Trop Med Hyg       Date:  1990 Sep-Oct       Impact factor: 2.184

4.  Measurement of serum antibodies against native Leishmania gp63 distinguishes between ongoing and previous L. donovani infection.

Authors:  E A Okong'o-Odera; J A Kurtzhals; A S Hey; A Kharazmi
Journal:  APMIS       Date:  1993-08       Impact factor: 3.205

5.  Abnormal IgG4 antibody response to aeroallergens in allergic patients.

Authors:  P Jeannin; Y Delneste; I Tillie-Leblond; B Wallaert; A carlier; J Pestel; A B Tonnel
Journal:  Int Arch Allergy Immunol       Date:  1994       Impact factor: 2.749

6.  Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis.

Authors:  E M Carvalho; O Bacellar; C Brownell; T Regis; R L Coffman; S G Reed
Journal:  J Immunol       Date:  1994-06-15       Impact factor: 5.422

7.  Detection and characterization by immunoblot analysis of potentially diagnostic Leishmania infantum polypeptides in human visceral leishmaniasis.

Authors:  N Cardeñosa; C Riera; P Cortés; F March; C Muñoz; M Portús; G Prats
Journal:  Parasite Immunol       Date:  1995-10       Impact factor: 2.280

8.  Schistosoma mansoni cercaria and schistosomulum antigens in serodiagnosis of schistosomiasis.

Authors:  H Y Kanamura; S Hoshino-Shimizu; L C da Silva
Journal:  Bull Pan Am Health Organ       Date:  1992

9.  Serological investigations on Indian kala-azar.

Authors:  A C Ghose; J P Haldar; S C Pal; B P Mishra; K K Mishra
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

10.  Ethiopian visceral leishmaniasis patients co-infected with human immunodeficiency virus.

Authors:  N Berhe; A Hailu; D Wolday; Y Negesse; P Cenini; D Frommel
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Mar-Apr       Impact factor: 2.184

View more
  15 in total

1.  Significance of persistence of antibodies against Leishmania infantum in Sicilian patients affected by acute visceral leishmaniasis.

Authors:  Pasquale Mansueto; Ilenia Pepe; Aurelio Seidita; Francesca Scozzari; Giustina Vitale; Francesco Arcoleo; Inglese Elvira; Enrico Cillari; Giovam Battista Rini; Nicola Napoli; Salvatore Di Rosa; Serafino Mansueto; Gaetana Di Fede
Journal:  Clin Exp Med       Date:  2011-06-29       Impact factor: 3.984

2.  Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.

Authors:  Samiran Saha; Tuhina Mazumdar; Khairul Anam; Rajesh Ravindran; Bibhas Bairagi; Bibhuti Saha; Ramapada Goswami; Netai Pramanik; Subhashis K Guha; Sourjya Kar; Dwijadas Banerjee; Nahid Ali
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

3.  Detection of anti-leishmania (Leishmania) chagasi immunoglobulin G by flow cytometry for cure assessment following chemotherapeutic treatment of American visceral leishmaniasis.

Authors:  Elenice Moreira Lemos; Izabelle Teixeira Gomes; Sílvio Fernando Guimarães Carvalho; Roberta Dias Rodrigues Rocha; Jauber Fornaciari Pissinate; Olindo Assis Martins-Filho; Reynaldo Dietze
Journal:  Clin Vaccine Immunol       Date:  2007-03-14

4.  Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy.

Authors:  Rajesh Ravindran; Khairul Anam; Bibhas C Bairagi; Bibhuti Saha; Netai Pramanik; Subhasis K Guha; Rama P Goswami; Dwijadas Banerjee; Nahid Ali
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

5.  Vaccine Development Against Leishmania donovani.

Authors:  Amrita Das; Nahid Ali
Journal:  Front Immunol       Date:  2012-05-15       Impact factor: 7.561

Review 6.  In vitro activity and in vivo efficacy of a combination therapy of diminazene and chloroquine against murine visceral leishmaniasis.

Authors:  Samuel W Mwololo; Joshua M Mutiso; John C Macharia; Alain J Bourdichon; Michael M Gicheru
Journal:  J Biomed Res       Date:  2015-03-04

7.  Transcription of Toll-Like Receptors 2, 3, 4 and 9, FoxP3 and Th17 Cytokines in a Susceptible Experimental Model of Canine Leishmania infantum Infection.

Authors:  Shazia Hosein; Alhelí Rodríguez-Cortés; Damer P Blake; Karin Allenspach; Jordi Alberola; Laia Solano-Gallego
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

8.  Natural Mosquito-Pathogen Hybrid IgG4 Antibodies in Vector-Borne Diseases: A Hypothesis.

Authors:  Berlin Londono-Renteria; Jenny C Cardenas; Andrea Troupin; Tonya M Colpitts
Journal:  Front Immunol       Date:  2016-09-29       Impact factor: 7.561

9.  Immunobiology of visceral leishmaniasis.

Authors:  Rajiv Kumar; Susanne Nylén
Journal:  Front Immunol       Date:  2012-08-14       Impact factor: 7.561

10.  Serological and infection statuses of dogs from a visceral leishmaniasis-endemic area.

Authors:  Daniela Farias Laranjeira; Vânia Lúcia Ribeiro da Matta; Thaíse Yumie Tomokane; Mary Marcondes; Carlos Eduardo Pereira Corbet; Márcia Dalastra Laurenti
Journal:  Rev Saude Publica       Date:  2014-08       Impact factor: 2.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.